There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on OptimizeRx (OPRX – Research Report), MiMedx Group (MDXG – Research Report) and Petmed Express (PETS – Research Report) with bullish sentiments.
OptimizeRx (OPRX)
Lake Street analyst Eric Martinuzzi maintained a Buy rating on OptimizeRx today and set a price target of $17.00. The company’s shares closed last Friday at $10.12.
According to TipRanks.com, Martinuzzi is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for OptimizeRx with a $16.17 average price target, implying a 69.9% upside from current levels. In a report issued on April 16, JMP Securities also maintained a Buy rating on the stock with a $15.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
MiMedx Group (MDXG)
In a report released today, Brooks O’Neil from Lake Street maintained a Buy rating on MiMedx Group, with a price target of $12.00. The company’s shares closed last Friday at $6.27.
According to TipRanks.com, O’Neil has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on MiMedx Group is a Strong Buy with an average price target of $12.25, a 96.0% upside from current levels. In a report released today, Craig-Hallum also assigned a Buy rating to the stock.
Petmed Express (PETS)
In a report released today, Ryan Meyers from Lake Street maintained a Buy rating on Petmed Express, with a price target of $9.00. The company’s shares closed last Friday at $4.02, close to its 52-week low of $3.95.
According to TipRanks.com, Meyers has 0 stars on 0-5 stars ranking scale with an average return of
Petmed Express has an analyst consensus of Moderate Buy, with a price target consensus of $9.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on OPRX:
- OptimizeRx Provides Business Update and Sets First Quarter 2024 Conference Call for May 14, 2024 at 4:30 p.m. ET
- OptimizeRx sees Q1 revenue $18.5M-$19.2M, consensus $17.03M
- OptimizeRx Releases 2024 Environmental, Social, and Governance (ESG) Report
- Navigating New Horizons: Optimizerx Corporation’s Strategic Pivot Raises Financial Risk Flags
- OptimizeRx sees FY24 revenue at least $100M, consensus $104.73M
